Introduction
============

Drug addiction is defined as a chronic brain disease characterized by compulsive use of the drug, loss of control in drug intake and the emergence of a negative emotional state that is exacerbated by abstinence. In this context, opioids are highly addictive drugs of abuse linked with potent positive (pleasure/gratification) and negative (anxiety/stress) reinforcing effects ([@B21]). Preclinical studies also indicate that sex plays a critical role in drug addiction. In this sense, it has been shown that female rats have higher cocaine choice than males and the ovariectomization of rats reduces the cocaine choice ([@B20]). On the other hand, fluctuations in sex hormone levels during the estrous cycle may or may not affect the self-administration of drugs of abuse. For example, cocaine choice is not affected during estrous cycle ([@B20]), while heroin choice (an opioid most commonly used as a recreational drug for its euphoric effects) is reduced during proestrus phase of estrous cycle ([@B23]). In addition, clinical studies have been shown prevalence that the abuse for opioid analgesics and tranquilizers is higher in women than men ([@B48]), women increase drug intake and develop dependence more quickly than men ([@B3]) and when levels of estrogens are high and progesterone is low (follicular phase) the rewarding effects of cocaine are greater than the effects observed during luteal phase (progesterone is high) ([@B39]). These sex differences are associated with a modulation of the reward system (mesolimbic pathway) by sex hormones ([@B10]; [@B4]; [@B5]). The mesolimbic pathway is comprised of dopamine (DA) neurons from the ventral tegmental area (VTA) projecting primarily to the nucleus accumbens (NAcc). This circuit is activated by natural rewards ([@B31]; [@B1]) or drugs of abuse such as morphine ([@B11]), through an increase in NAcc DA release. It is known that DA neurons express androgen, estrogen and progesterone receptors ([@B22]; [@B35]; [@B8]), so sex differences observed in human and animals studies could be explained in part by the activation of these receptors by sex hormones and the concomitant regulation in the expression of key proteins involved in DA neurotransmission (for review see [@B42]; [@B4]). The search for factors that can explain sex differences in vulnerability to drugs of abuse has led to the study of sensitive periods of development where various organs are immature. Accordingly, fetal and neonatal stages are periods highly sensitive to deleterious stimuli that can reprogram the normal physiology of different organs such as the brain. Our group has shown that neonatal exposure to estradiol affects dopaminergic brain areas involved in prolactin release (tuberoinfundibular pathway) ([@B44]), movement (nigrostriatal pathway) ([@B9]) and reward (mesolimbic pathway) ([@B6]) in adulthood. We observed that neonatal administration of estradiol valerate (EV) increased DA levels and tyrosine hydroxylase (TH) expression in midbrain dopamine neurons of adult rats ([@B9]; [@B13]; [@B6]). The increase in DA content is functionally associated with greater NAcc DA release induced by chemical depolarization with K^+^ ([@B13]) or by electrical stimulation ([@B6]). However, it has not been evaluated whether neonatal exposure to estradiol favors greater reward effects induced by morphine in adulthood. The aim of the present study was to investigate the influence of neonatal administration of EV and testosterone propionate (TP) on morphine-induced NAcc DA release, conditioned place preference (CPP) and locomotor stimulation in adult male and female rats. In addition, in accordance with The National Institutes of Health (NIH) guidelines ([@B26]; [@B28]), this study was focused in the effects of neonatal sex hormones administration in male and female rats. We postulate that neonatal EV and TP administration will increase morphine activating effects such as NAcc DA release, CPP and locomotor activity in adult male and female rats.

Materials and Methods {#s1}
=====================

Animals
-------

105 males and 97 females Sprague Dawley pups from 16 litters were considered for the experiments. However, we excluded 14 rats (9 males and 5 females) that showed obvious signs of stress such as weight loss, porphyric secretions, piloerection and aggression behaviors, between others. The analyses were performed using 188 rats (96 males and 92 females) that showed a good state of health and they were assigned to the following experimental groups: female control (*n* = 29), male control (*n* = 34), female EV (*n* = 34), male EV (*n* = 33), female TP (*n* = 29) and male TP (*n* = 29). All rats were kept under the same conditions of temperature (21 ± 2°C), 12-h light-dark cycle (lights on at 08:00 h), food and water *ad libitum*. All experimental procedures were approved by the Ethics and Biosafety Committee from the Universidad de Valparaíso, and the Institutional Animal Experimentation Ethics Board and the Science Council (FONDECYT) of Chile. Efforts were made to minimize the number of rats used and their suffering.

Drugs and Reagents
------------------

EV, TP, sesame oil, DA standard, EDTA, and 1-octanesulfonic acid were purchased from Sigma-Aldrich, Inc. (St. Louis, MO, United States). Morphine hydrochloride was obtained from Laboratorio Sanderson S.A. (ISPCH N° F-10903/16, Santiago, Chile). All other reagents were of analytical and molecular grade.

Experimental Procedure
----------------------

Male and female pups were single-injected at postnatal day (PND) 1 with EV (0.1 mg/50 μL of sesame oil s.c.), TP (0.1 mg/50 μL of sesame oil s.c.) or vehicle (control group: 50 μL of sesame oil s.c.). The doses of EV and TP used were previously published and produce long-term effects in reproductive and non-reproductive tissues such as the brain ([@B44]; [@B9]; [@B13]). All pups were raised with a nursing mother until weaning age (PND21). After weaning, rats were housed in standard cages by experimental group and sex under the aforementioned vivarium conditions until PND60 for male and PND60-62 for female rats. Control females were tested in the diestrus phase of their cycles because both the EV and TP exposed rats treated rats are constantly arrested in this stage of the estrous (by action of the neonatal administration of hormones) ([@B9]). The stage of estrous cycle was daily recorded from PND40 to the end of the study (PND60-62). The estrous cycle was assessed by analyzing the relative proportion of leukocytes, epithelial cells, and cornified cells in daily vaginal lavages, which characteristically change during the various stages of the estrous cycle. All the experimental groups were randomly assigned for the following experimental protocols.

Determination of NAcc DA Release
--------------------------------

We used *in vivo* brain microdialysis in anesthetized rats following a general protocol previously published ([@B43], [@B41]). Basal and morphine-induced DA extracellular levels were measured through high performance liquid chromatography (HPLC) coupled to electrochemical detection (ED). Rats used for microdialysis experiments were 9 (4 females and 5 males), 10 (5 females and 5 males), and 9 (4 females and 5 males) for control, EV and TP groups, respectively.

### *In vivo* Brain Microdialysis

At PND60, rats were deeply anesthetized with isoflurane (5% in 0.6 L/min air flow) in an induction chamber and placed in a stereotaxic apparatus (model 68002, RWD Life Science Co. Ltd., Shenzhen, China) with a mask to maintain anesthesia for all the experiment (isoflurane 2% in 0.6 L/min air flow), using an animal anesthesia system (model 510, RWD Life Science Co. Ltd., Shenzhen, China). Body temperature was maintained at 37°C with an electrical blanket controlled by a thermostat. Concentric brain microdialysis probes (2 mm membrane length, model MAB 2.4.12, 35 kDa cut-off, Microbiotech AB, Stockholm, Sweden) were implanted in the NAcc using the coordinates from the Rat Brain Atlas ([@B30]) (NAcc: 1.50 mm posterior, 1.50 mm lateral, and 7.8 mm ventral to brain surface). Microdialysis probes were perfused with artificial cerebrospinal fluid (aCSF in mM: NaCl 147; KCl 2.7; CaCl~2~ 1.2; MgCl~2~ 0.85; pH 7.4) at a rate of 1 μL/min using an infusion pump (model RWD 210, RWD Life Science Co. Ltd., Shenzhen, China). After a stabilization period of 90 min, three perfusion samples were collected every 20 min in 3 μL of 0.2 M perchloric acid. At 60 min, an intravenous (i.v.) morphine injection (5 mg/kg) was administered to the rats. The dose of morphine has been previously published and injected by the same route of administration ([@B40]). Seven perfusion samples were collected after morphine injection and all the perfusion samples were maintained on ice during the experiment and stored at -80°C until analysis. At the end of each experiment, rats were euthanized by decapitation with a guillotine (model 51330, Stoelting^TM^ Co., Wood Dale, IL, United States) and brains were quickly removed and stored in formalin. Brain sections of 50 μm were stained with Leishman's eosin methylene blue solution (Cat. \#1.05387.0500, Merck KGaA, Darmstadt, Germany) to verify probe location. Placement of the microdialysis probe was examined microscopically.

### DA Quantification

Ten microliters of each dialysate sample were injected to the HPLC-ED system with the following equipment: An isocratic pump, (model PU-2080 Plus, Jasco Co. Ltd., Tokyo, Japan), a C18 column (model Kromasil 100-3.5-C18, AkzoNobel, Bohus, Sweden) and an electrochemical detector (set at 650 mV, 0.5 nA; model LC-4C, BAS, West Lafayette, IN, United States). The mobile phase, containing 0.1 M NaH~2~PO~4~, 1.0 mM 1-octanesulfonic acid, 1.0 mM EDTA and 8.0% (v/v) CH~3~CN (pH 3.4) was pumped at a flow rate of 125 μL/min. DA extracellular levels were assessed by comparing the respective peak area and elution time of the sample with a reference standard and the quantification was performed using a calibration curve for each neurotransmitter (Program ChromPass, Jasco Co. Ltd., Tokyo, Japan).

Behavioral Studies
------------------

One hundred and sixty rats were used for CPP (*n* = 90) and locomotor activity (*n* = 70) experiments.

### Conditioned Place Preference

Rats used for CPP were assigned to the following experimental groups: female control (*n* = 15), male control (*n* = 16), female EV (*n* = 16), male EV (*n* = 15), female TP (*n* = 14) and male TP (*n* = 14).

The CPP apparatus and the protocol used were previously described ([@B6]). Briefly, the conditioning protocol consisted of three parts: pre-test (one day before the conditioning period), the conditioning period and the test (24 h after the last injection). For the pre-test and the test, rats were placed in the neutral-gray center compartment with the two guillotine doors open and were allowed to explore the entire apparatus (two outer compartments) for 15 min. The time spent in each compartment was measured by analyzing the recordings obtained by internet protocol (IP) cameras (LX-C202 model; Lynx Security, China) fixed above each place preference apparatus and connected to a computer in another room. During the conditioning period (3 days) the non-preferred compartment (the white side) was associated with the reward induced by morphine (3 mg/kg s.c., once per day). The morphine dose and conditioning period used in this work it was previously published ([@B27]).

The time difference (ΔT) in seconds between the time spent in the white compartment on the test day and the pre-test day was used to determine the grade of conditioning in the rats.

### Locomotor Activity

Rats used for measure distance traveled were assigned to the following experimental groups: female control (*n* = 10), male control (*n* = 13), female EV (*n* = 13), male EV (*n* = 13), female TP (*n* = 11) and male TP (*n* = 10).

The protocol used for locomotor activity experiments was previously described ([@B9]; [@B12]). Briefly, rats were habituated to the test room for 1 h before starting the experimental protocol. Basal and morphine-induced horizontal locomotor activity was measured using an acrylic box (22 × 44 × 28 cm). Basal locomotor activity was registered for 30 min and then rats were injected with physiological saline solution (1 mL/kg, s.c.) or morphine (3 mg/kg, s.c.), recording the locomotor activity for 180 min. The dose of morphine used in our behavioral experiments was chosen to produce selective locomotor hyperactivity ([@B29]; [@B11]). Higher doses of morphine (between 10 and 30 mg/kg) produce sedation and thus, reduce locomotor activity ([@B25]; [@B45]). Each complete session of locomotor activity (210 min) was recorded with an IP camera (LX-C202 model; Lynx Security, China) and the total traveled distance (m) was analyzed using ANY-Maze software (Stoelting Co., Wood Dale, IL, United States). Test cages were wiped and cleaned with 5% ethanol solution between trials.

qRT-PCR
-------

Rats of the experimental groups injected with saline and used to measure locomotor activity were decapitated with a guillotine and the brain was removed. The NAcc was microdissected at 4°C using micro-punch, weighed on an analytical balance and stored at -80°C for further analysis. Real-time qRT-PCR was used to determine whether the mRNA encoding μ, D~1~ and D~2~ receptors changed in NAcc and VTA of adult female and male rats exposed to sex hormones at PND1. Total RNA was extracted using the E.Z.N.A.^®^ Total RNA Kit I (Cat. \#R6834-02; Omega Biotek) according to the manufacturer's instructions. RNA was quantified using the microplate Spectrophotometer Epoch (BioTek Inc., Winooski, VT, United States), and RNA integrity was assessed through agarose gel electrophoresis. Total RNA from each sample were reverse transcribed with PrimeScript RT reagent Kit (Cat. \#RR047A; TaKaRa, Bio Inc., CA, United States), according to the manufacturer's instructions. Real-time RT-PCR was performed using Taqman assays for the following genes purchased from Thermo Fisher Scientific: *Drd1* (Cat: Rn03062203_s1, FAM dye-labeled), *Drd2* (Cat: Rn00561126_m1, VIC dye-labeled) and *Oprm1* (Cat: Rn01430371_m1, FAM dye-labeled). The cycle conditions were 50°C for 2 min, 95°C for 2 min, 40 cycles for 95°C for 3 s and 60°C for 30 s. The relative quantification method was performed using Rn45s (Cat: Rn03928990_g1, VIC dye labeled) as an endogenous control. Results were expressed as fold change by the 2^-ΔΔCT^ method ([@B24]).

Statistical Analysis
--------------------

Data were expressed as mean ± SEM. Two-way ANOVA followed by Newman--Keuls *post hoc* test analysis were performed for all experiments to determine a significant interaction of treatment by sex. The statistical analyses were carried out with GraphPad Prism v6.0 (GraphPad Software, San Diego, CA, United States) and *P* \< 0.05 was considered statistically significant.

Results
=======

Our data show that neonatal exposure to EV increases the rewarding effects of morphine and it represents a vulnerability factor that may enhance the development of opioid dependence.

Long-Lasting Effects of Neonatal Sex Hormones Administration on Morphine-Induced NAcc DA Release in Adult Rats
--------------------------------------------------------------------------------------------------------------

[Figure 1A,B](#F1){ref-type="fig"} show time course of basal and morphine-induced extracellular levels of DA in NAcc. [Figure 1C](#F1){ref-type="fig"} shows the area under the curve (AUC) that represents morphine-induced DA extracellular levels in control, EV and TP adult rats. In this context, neonatal exposure to EV in female and male rats increases morphine-induced NAcc DA release in the adulthood respect to control rats injected with vehicle (Two-way ANOVA followed by Newman--Keuls *post hoc* analysis; Interaction \[*F*~(2,22)~ = 0.4001, *P* = 0.6751\]; Sex \[*F*~(1,22)~ = 3.328, *P* = 0.0817\]; treatment \[*F*~(2,22)~ = 10.17, *P* = 0.0007\]).

![Morphine-induced NAcc DA release using *in vivo* brain microdialysis. Panels **A** and **B** Time course of NAcc DA release expressed as percentage of baseline (mean ± SEM) in female **(A)** and male **(B)** adult rats exposed to neonatal administration to estradiol valerate (EV) or testosterone propionate (TP). At postnatal day (PND) 60 microdialysis experiments were performed and after a stabilization period, three perfusion samples were collected. At 60 min a dose of morphine (5 mg/kg, i.v.) was injected. **(C)** shows an increase in the area under the curve (AUC) of morphine-induced NAcc DA release in female (F) and male (M) adult rats. ^∗^*P* \< 0.05 for EV female rats vs. control female rats and for EV male rats vs. control male rats.](fphar-10-00295-g001){#F1}

Long-Lasting Effects of Neonatal Sex Hormones Administration on Morphine-Induced CPP in Adult Rats
--------------------------------------------------------------------------------------------------

[Figure 2](#F2){ref-type="fig"} shows morphine-induced conditioned behavior in female and male adult rats exposed during the first 12 h of postnatal life to a single dose of EV or TP. As expected, morphine administration (3 mg/kg, s.c.) produced a significant increase in the time spent in the chamber paired to morphine injection vs. saline injection in female and male rats in all experimental groups (^∗∗∗∗^*P* \< 0.0001). (Two-way ANOVA followed by Newman--Keuls *post hoc* analysis; Interaction \[*F*~(5,78)~ = 0.5782, *P* = 0.7166\]; Sex \[*F*~(1,78)~ = 11.64, *P* = 0.0010\]; treatment \[*F*~(5,78)~ = 71.88, *P* \< 0.0001\]).

![Conditioned place preference (CPP) to saline or morphine of adult female (F) and male (M) rats exposed to estradiol valerate (EV) and testosterone propionate (TP) at postnatal day (PND) 1. Data are shown as the time difference (ΔT) in seconds between the time spent in the white compartment in the test day and the pre-test day. Neonatal exposure to EV in female and male rats increases CPP induced by morphine (3 mg/kg, s.c.) respect neonatal injection of vehicle in female and male rats at PND 60 (^∗∗∗∗^*P* \< 0.0001).](fphar-10-00295-g002){#F2}

Long-Lasting Effects of Neonatal Sex Hormones Administration on Morphine-Induced Locomotor Activity in Adult Rats
-----------------------------------------------------------------------------------------------------------------

[Figure 3A,C](#F3){ref-type="fig"} show the temporal course of locomotor activity in the experimental groups that received only the saline (1 mL/kg, s.c.) injection. Morphine-induced locomotor activity was measured in adult female ([Figure 3B](#F3){ref-type="fig"}) and male ([Figure 3D](#F3){ref-type="fig"}) rats exposed during the first hours of postnatal life to EV or TP. [Figure 4](#F4){ref-type="fig"} shows basal (4A: 0--30 min) and post-injection (4B: 30--210 min) cumulative locomotor activities between experimental groups. Basal cumulative locomotor activity ([Figure 4A](#F4){ref-type="fig"}) was not different in our experimental groups (Two-way ANOVA followed by Newman--Keuls *post hoc* analysis; Interaction \[*F*~(5,58)~ = 1.012, *P* = 0.4192\]; Sex \[*F*~(1,58)~ = 3.424, *P* = 0.0694\]; treatment \[*F*~(5,58)~ = 1.102, *P* = 0.3695\]). [Figure 4B](#F4){ref-type="fig"} shows that cumulative locomotor activity induced by morphine (30 to 210 min) was significantly higher than cumulative locomotor activity produced by saline injection (^∗^*P* \< 0.05, ^∗∗∗^*P* \< 0.001, ^∗∗∗∗^*P* \< 0.0001). On the other hand, control and EV female rats have a greater cumulative locomotor activity induced by morphine than control and EV male rats induced by morphine (^\$^*P* \< 0.05) (Two-way ANOVA followed by Newman--Keuls *post hoc* analysis; Interaction \[*F*~(5,58)~ = 2.140, *P* = 0.0733\]; Sex \[*F*~(1,58)~ = 9.909, *P* = 0.0026\]; treatment \[*F*~(5,58)~ = 32.48, *P* \< 0.0001\]).

![Time course of basal, saline-induced and morphine-induced locomotor activity in female **(A,B)** and male **(C,D)** control, EV and TP rats expressed in distance traveled (m).](fphar-10-00295-g003){#F3}

![Morphine-induced locomotor activity in adult female (F) and male (M) rats exposed to estradiol valerate (EV) or testosterone propionate (TP) at PND 1. Cumulative locomotor activity from 0 to 30 min (basal) **(A)** and from 30 to 210 min (**B**, induced by saline or morphine injection) in female (F) and male (M) control, EV and TP rats ^∗^*P* \< 0.05, ^∗∗∗^*P* \< 0.001 and ^∗∗∗∗^*P* \< 0.0001 versus saline female or saline male rats, respectively. ^\$^*P* \< 0.05 versus respective male rats.](fphar-10-00295-g004){#F4}

Neonatal Exposure to Sex Hormones Does Not Affect the mRNA Expression of DA and μ Opioid Receptors in NAcc in Adulthood
-----------------------------------------------------------------------------------------------------------------------

mRNA expression for *Drd1* ([Figure 5A](#F5){ref-type="fig"}), *Drd2* ([Figure 5B](#F5){ref-type="fig"}), and μ opioid receptors ([Figure 5C](#F5){ref-type="fig"}) were measured in NAcc of adult rats exposed during the first hours of post-natal life to a single dose of sex hormones. We did not observed a significant increase in *Drd1* (Two-way ANOVA followed by Newman--Keuls *post hoc* analysis; Interaction \[*F*~(2,30)~ = 0.1006, *P* = 0.9046\]; Sex \[*F*~(1,30)~ = 0.08264, *P* = 0.7757\]; treatment \[*F*~(2,30)~ = 1.988, *P* = 0.1546\]), *Drd2* (Two-way ANOVA followed by Newman--Keuls *post hoc* analysis; Interaction \[*F*~(2,30)~ = 0.1482, *P* = 0.8629\]; Sex \[*F*~(1,30)~ = 0.1634, *P* = 0.6889\]; treatment \[*F*~(2,30)~ = 3.076, *P* = 0.0609\]) and *Oprm1* (Two-way ANOVA followed by Newman--Keuls *post hoc* analysis; Interaction \[*F*~(2,30)~ = 1.040, *P* = 0.3659\]; Sex \[*F*~(1,30)~ = 3.757, *P* = 0.0620\]; treatment \[*F*~(2,30)~ = 0.1506, *P* = 0.8608\]), expressions in NAcc.

![Neonatal exposure to estradiol valerate (EV) and testosterone propionate (TP) does not affect the expressions of *Drd1* **(A)**, *Drd2* **(B)**, and *Oprm1* **(C)** in nucleus accumbens (NAcc) of adult female (F) and male (M) rats. All data have been normalized for levels of 18S expression within the same sample. Results are expressed as fold of induction regard control group and represent the mean ± SEM.](fphar-10-00295-g005){#F5}

Discussion
==========

We have shown that neonatal EV administration produces a higher increase in morphine-induced NAcc DA release in both female and male adult rats compared to control rats. This effect correlates with a higher increase in morphine-induced CPP and locomotor activity in EV treated rats compared to controls. These findings indicate that neonatal exposure to sex hormones, especially estradiol, could reprogram the reward system and consequently alter to neurochemical, rewarding and behavioral activating effects of morphine in adult female and male rats.

Neonatal Administration of Sex Hormones Increases Morphine-Induced NAcc DA Release in Adult Male and Female Rats
----------------------------------------------------------------------------------------------------------------

Morphine injection produces an increase in NAcc DA release in adult rats exposed during the first hours of postnatal life to EV compared to control and TP rats. Morphine is an opiate found naturally in the opium poppy plant and it is used therapeutically as a narcotic analgesic. One of the most important adverse effects of morphine is the highly addictive potential (similar to heroin). At the neurochemical level, morphine increases extracellular levels of DA in the NAcc ([@B11]; [@B46]). In our experiments, neonatal EV exposure in rats produced an increase in NAcc DA release ([Figure 1](#F1){ref-type="fig"}), CPP ([Figure 2](#F2){ref-type="fig"}), and locomotor activity ([Figure 3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}) induced by morphine compared to control or TP-treated rats. In this context, several studies have shown that estradiol facilitates the motivation for drugs of abuse by interacting with reward system ([@B50]). For example, estradiol increases cocaine self-administration, cocaine intake and motivation in ovariectomized rats (OVX) ([@B17]; [@B34]). On the other hand, locomotor activity induced by cocaine is lower in OVX than control (intact) rats ([@B49]). The neural and behavioral effects of estradiol on DA neurons have been associated with changes in expression levels of DA key proteins such as TH (rate-limiting enzyme of catecholamine biosynthesis), DAT (protein responsible for regulating DA levels through the uptake of DA) and DA receptors. In this sense, in OVX rats have been observed a reduction in levels of VTA TH and NAcc DAT that are restores after hormone replacement therapy ([@B7]; [@B18]). However, D~2~ levels are increased in NAcc and dorsolateral striatum (DLS) of OVX rats to compare controls rats and the estradiol replacement reduced D~2~ levels in NAcc and DLS of OVX rats ([@B7]). The estradiol effects on these proteins are mediated by the activation of specific receptor such as estrogen receptor α (ERα) and estrogen receptor β (ERβ) expressed in reward system resulting in up- or down-regulation of gene expression ([@B38]; [@B36]; [@B8]). On the other hand, G protein-coupled estrogen receptor (GPER) produces rapid pharmacological response to estradiol ([@B14]). In NAcc and DLS the activation of GPER increases DA release induced by psychostimulant drugs in female rats ([@B2]; [@B10]).

Regard our data, we previously demonstrated that neonatal exposure to EV during the first hours of postnatal life results in higher DA content in the mesolimbic pathway (VTA and NAcc) ([@B9]; [@B13]) and increased NAcc DA release induced be a depolarizing stimulus (70 nM K^+^) ([@B13]; [@B6]). In addition, neonatal exposure to EV reprograms the electrophysiological properties of VTA DA neurons, favoring a higher firing frequency compared to control rats ([@B6]). All of these alterations in the dopaminergic system induced by neonatal EV administration may contribute to the increased morphine-induced NAcc DA release in EV rats.

Another possible mechanism involved in the increased morphine-induced NAcc DA release in adult rats exposed to EV during the first hours of life ([Figure 1](#F1){ref-type="fig"}) might be a decrease in the inhibitory effect of GABAergic neurons on midbrain DA neurons. It has been shown that neonatal estradiol benzoate administration results in an enhanced PFC DA release in adult female rats and a decrease in brain levels of allopregnanolone (a potent neurosteroid that is a positive modulator of GABA~A~ receptors) when compared to control rats ([@B32]). In addition, we showed that EV female adult rats have a decrease in GABA content in tuberal hypothalamus ([@B44]). Therefore, it is possible that this decrease in GABA content could also occur in the VTA, reducing the tonic inhibition of VTA DA neurons. Furthermore, the hyperpolarizing effect of morphine on VTA GABA neurons ([@B16]; [@B19]) in EV rats may favors a greater NAcc DA release than control rats. Interestingly, it has been shown that estradiol also stimulates VTA DA neurons through the inhibition of GABAergic afferents from medial preoptic area (anterior hypothalamus) to VTA, producing an increase in firing of DA neurons ([@B47]).

Neonatal Administration of Sex Hormones Increases Morphine-Induced CPP and Locomotor Activity in Adult Male and Female Rats
---------------------------------------------------------------------------------------------------------------------------

The repeated administration of morphine (3 mg/kg s.c.) results in conditioning in rats of both sexes. Interestingly, the degree of conditioning induced by morphine was higher in adult EV rats compared to control rats ([Figure 2](#F2){ref-type="fig"}), reflecting the development of a more intense reward that could be associated to the increased NAcc DA release induced by morphine in EV rats ([Figure 1](#F1){ref-type="fig"}). The neonatal exposure to EV not only produced an increase in CPP behavior associated to repeated morphine administration in adult rats ([Figure 2](#F2){ref-type="fig"}), but also an increase in locomotor activity in response to an acute administration of morphine (see [Figure 3](#F3){ref-type="fig"}). The dose of morphine used in this work was effective to induce locomotor activity when compared to saline injection in all experimental groups. Interestingly, although the basal locomotor activity ([Figure 3](#F3){ref-type="fig"}) measured during first 30 min (in the absence of injection of saline or morphine) in all experimental groups were not different, we observed an increase in the locomotor activity induced by morphine regard to saline injection (30 to 210 min) ([Figure 3](#F3){ref-type="fig"}).

In female EV rats the morphine-induced locomotor activity was higher compared to female control rats, while in the case of male rats, administration of both EV and TP resulted in an enhanced locomotor activity after acute morphine compared to control male rats ([Figure 4](#F4){ref-type="fig"}). These neurochemical and behavioral results demonstrate that DA neurons programmed with sex hormones are susceptible to greater activation by opioids such as morphine. In this context, the effect observed in TP male rats on morphine-induced locomotor activity might result from partial aromatization of testosterone (T) to estradiol (E~2~) through cytochrome P450 aromatase, which is highly expressed in the midbrain ([@B33]). In previous work, we observed an increase in TH expression and DA levels in the substantia nigra and VTA in TP and EV male rats compared to controls. But, males treated with dihydrotestosterone (DHT), a non-aromatizable androgen at postnatal day 1 did not show changes in those parameters compared with controls, suggesting an estrogenic mechanism ([@B13]). On the other hand, published studies in intact female rats in diestrous phase of estrous cycle have a self-administration to drugs of abuse similar to males ([@B20]; [@B23]), in this work we observed that the neonatal administration of EV increases morphine-induced behaviors compared to control rats also in diestrous phase. Our results could suggest that the long-term effects observed on dopaminergic neurons by neonatal exposure to sex hormones could be due to permanent epigenetic changes. However, future studies would be needed.

Our results do not show changes in NAcc *Drd1* and *Drd2* expressions in female and male rats treated with EV and TP ([Figure 5](#F5){ref-type="fig"}). In addition, we did not observe changes in NAcc μ opioid receptor expression, which suggests that the increase in the rewarding properties of morphine in EV rats might be due to an increase in DA synthesis ([@B6]) and DA release rather than changes in receptor expressions. However, the expression of proteins downstream of the activation of DA receptors should be explored, especially changes in the expression of the regulators of G-protein signaling (RGS) that are involved in locomotor responses to drugs of abuse ([@B15]) and modulated by estrogens ([@B37]).

Conclusion
==========

In conclusion, the alteration of sex hormones homeostasis during the early stages of development, either by a supra-physiological exposure to these hormones or by persistent exposure to endocrine disruptors (environmental pollutants) with estrogenic activity produce long-term effects not only in reproductive tissues, but also in non-reproductive tissues such as the brain. In this context, neonatal exposure to sex hormones can be considered a factor of vulnerability for substance use disorders such as morphine addiction and abuse. Finally, our experimental model of neonatal reprogramming allows exploration of the epigenetic mechanisms involved in DA neurons that may be responsible for the long-term effects observed in this work.
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